|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR1900027886 |
|
最近更新日期: Date of Last Refreshed on: |
2019-12-02 21:39:26 |
|
注册时间: Date of Registration: |
2019-12-02 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
经颈内静脉门体分流术对肠道微生态影响的临床研究 |
|
Public title: |
Clinical study on the effect of transjugular portal shunt on intestinal microecology |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
经颈内静脉门体分流术对肠道微生态影响的临床研究 |
|
Scientific title: |
Clinical study on the effect of transjugular portal shunt on intestinal microecology |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄圣杰 |
研究负责人: |
杨仕明 |
|
Applicant: |
Shengjie Huang |
Study leader: |
Shiming Yang |
|
申请注册联系人电话: Applicant telephone: |
+86 13883948867 |
研究负责人电话: Study leader's telephone: |
+86 13228686589 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
505543630@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
shimingyang@yahoo.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝中区医学院路1号 |
研究负责人通讯地址: |
重庆市沙坪坝区新桥正街83号 |
|
Applicant address: |
1 Yixueyuan Road, Yuzhong District, Chongqing, China |
Study leader's address: |
83 Xinqiao Main Street, Shapingba District, Chongqing, China. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
400037 |
|
|
申请人所在单位: |
重庆医科大学 |
||
|
Applicant's institution: |
Chongqing Medical University |
||
|
研究负责人所在单位: |
新桥医院消化科 |
||
|
Affiliation of the Leader: |
Department of Gastroenterology, Xinqiao Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2019-研第082-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军陆军军医大学第二附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Second Affiliated Hospital of Amy Medical University, PLA |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2019-07-23 00:00:00 |
||
|
伦理委员会联系人: |
邓璠 |
||
|
Contact Name of the ethic committee: |
Fan Deng |
||
|
伦理委员会联系地址: |
重庆市沙坪坝区新桥正街83号新桥医院药学部 |
||
|
Contact Address of the ethic committee: |
Department of Pharmacy, Xinqiao Hospital, 83 Xinqiao Main Street, Shapingba District, Chongqing, China. |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
新桥医院消化科 |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Gastroenterology, Xinqiao Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市沙坪坝区新桥正街83号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
83 Xinqiao Main Street, Shapingba District, Chongqing, China. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
科室自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-raised funds |
||||||||||||||||||||||
|
Target disease: |
portal hypertension |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
评价经颈内静脉门体分流术对肠道菌群稳态的影响,为经颈内静脉门体分流术后肠道菌群变化对患者预后提供医学证据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effect of transjugular portal shunt on intestinal flora homeostasis and provide medical evidence for the prognosis of patients with intestinal flora changes after transjugular portal shunt |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄18-70岁、男女不限。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. aged 18-70 years, gender not limited. |
||||||||||||||||||||||
|
排除标准: |
1. 经 CT 或 MRI、组织病理学等检查证实肝硬化合并肝癌或组织病理证实存在胃癌、胰腺癌等其他恶性肿瘤的患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients confirmed by CT or MRI, histopathology and other examinations that cirrhosis complicated with liver cancer or histopathology confirmed the presence of gastric cancer, ancreatic cancer or other malignant tumors |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-07-22 00:00:00至 To 2020-07-22 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-01-01 00:00:00 至 To 2020-07-22 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
未使用随机方非,以符合入组标准的肝硬化失代偿期患者行Tips术前术后进行自身对照研究。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Non-randomization, patients with decompensated cirrhosis who met the criteria for inclusion received preoperative and postoperative Tips for self-controlled study. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
需要者向研究组织者索取 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Requested by the research organizer |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
(1) 研究单位设1名监察员,监察员每天核查入组病例CRF填写的准确性和完整性,每周汇总上报单位负责人;单位负责人每周核查入组病例及其CRF填写情况,及时发现并整改问题; (2) 该临床验证试验过程中具体处方医生不参与临床性能评价、资料整理和统计分析,而这些工作由另外不知道试验分组情况和具体情况的专业人员完成。 (3) 数据库建立后,不得更改,由研究团队以外的专业统计人员(盲法)负责统计分析完成。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
(1) the research unit shall have one supervisor, who shall check the accuracy and completeness of CRF filling in enrolled cases every day, summarize and report to the head of the unit every week;The responsible person of the unit shall check the enrolled cases and their CRF fillings every week, and timely discover and rectify problems; (2) The prescribing physicians did not participate in the clinical performance evaluation, data collation, and statistical analysis during the clinical validation trial, and these tasks were performed by other professionals who did not know the grouping and specific conditions of the trial. (3) after the establishment of the database, it shall not be changed, and professional statisticians (blind method) other than the research team shall be responsible for the completion of statistical analysis. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |